vaxneuvance 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 4 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+
merck sharp & dohme bh d.o.o. - pneumokokus, prečišćeni polisaharidni antigen konjugovani - suspenzija za injekciju u napunjenoj šprici - 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 4 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml+ 2 µg/0.5 ml - jedna doza (0,5 ml) sadrži 2 µg pneumokoknog polisaharida serotipova 1, 3, 4, 5, 6a, 7f, 9v, 14, 18c, 19a, 19f, 22f, 23f i 33f i 4 µg serotipa 6b, konjugovanih na proteinski nosač crm197
nimenrix
pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningitis, meningokokal - cjepiva - nimenrix je indiciran za aktivnu imunizaciju osoba od dobi od 6 tjedana protiv invazivnih meningokoknih bolesti uzrokovanih neisseria meningitidis grupom a, c, w-135 i y.
tecfidera
biogen netherlands b.v. - dimetil fumarat - multipla skleroza - imunosupresivi - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).
dimethyl fumarate mylan
mylan ireland limited - dimetil fumarat - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetil fumarat - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate teva
teva gmbh - dimetil fumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate accord
accord healthcare s.l.u. - dimetil fumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
prevenar 13
pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f - pneumococcal infections; immunization - cjepiva - aktivna imunizacija za prevenciju invazivnih bolesti, pneumonije i akutnog otitis medija uzrokovana streptococcus pneumoniae kod dojenčadi, djece i adolescenata od 6 tjedana do 17 godina starosti. aktivna imunizacija za sprječavanje invazivnih bolesti uzrokovane streptococcus pneumoniae kod odraslih ≥18 godina i starije. pogledajte odjeljke 4. 4 i 5. 1 za informacije o zaštiti od specifičnih pneumokoknih serotipova. korištenje Превенар 13 mora biti definiran na temelju službenih preporuka, uzimajući u obzir rizik od invazivnih bolesti u različitim dobnim skupinama, leži u osnovi srodne bolesti, kao i varijabilnost серотипа za epidemiologiju u različitim zemljopisnim područjima.
synflorix
glaxosmithkline biologicals s.a. - pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19f - pneumococcal infections; immunization - cjepiva - aktivna imunizacija protiv invazivnih bolesti i akutnih otitis media uzrokovanih streptococcus pneumoniae kod dojenčadi i djece od šest tjedana do pet godina. pogledajte odjeljke 4. 4 i 5. 1 u informacijama o proizvodu za informacije o zaštiti od specifičnih pneumokoknih serotipova. primjena cjepivo synflorix mora odrediti na temelju službenih preporuka, uzimajući u obzir utjecaj invazivne bolesti u različitim dobnim skupinama, kao i varijabilnost серотип za epidemiologiju u različitim zemljopisnim područjima.